Cargando…
Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned
There are 670 million people at risk of contracting lymphatic filariasis (LF) in India, which bears 40% of the global burden of the disease. The National Program to Eliminate LF was launched in 2004 first with a single-drug therapy—diethylcarbamazine (DEC), followed by a two-drug therapy—DEC + alben...
Autores principales: | Tripathi, Bhupendra, Roy, Nupur, Dhingra, Neeraj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154644/ https://www.ncbi.nlm.nih.gov/pubmed/35292580 http://dx.doi.org/10.4269/ajtmh.21-0964 |
Ejemplares similares
-
Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India
por: Sabesan, S., et al.
Publicado: (2022) -
Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin–Diethylcarbamazine–Albendazole for Lymphatic Filariasis Elimination
por: Ghosh, Raj Shankar, et al.
Publicado: (2022) -
A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery
por: Weil, Gary J, et al.
Publicado: (2020) -
Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis
por: Jacobson, Julie
Publicado: (2022) -
Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China
por: Fang, Yuan, et al.
Publicado: (2019)